BCG-Unresponsive NMIBC and Treatments

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.

EP: 1.Standard of Care in NMIBC

Now Viewing

EP: 2.BCG-Unresponsive NMIBC and Treatments

EP: 3.Recent FDA Approvals in NMIBC

EP: 4.Selecting Treatment for BCG-Unresponsive NMIBC

EP: 5.BOND-003 Trial and Cretostimogene for Treatment of NMIBC

EP: 6.Other Emerging Intravesical Therapies in NMIBC

EP: 7.Emerging Immunotherapies in NMIBC

EP: 8.Future of BCG in NMIBC

Video content above is prompted by the following:

• When do you consider a patient to have BCG-unresponsive disease?
• What treatment options are available for BCG-unresponsiveness/intolerance in patients?

Related Videos

Related Content

Advertisement

February 24th 2025

Neoadjuvant APL-1202 plus tislelizumab is safe in patients with MIBC

Hannah Clarke

The pCR rate was 33% with APL-1202 plus tislelizumab compared with 26% with tislelizumab alone.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Related Content

Advertisement

February 24th 2025

Neoadjuvant APL-1202 plus tislelizumab is safe in patients with MIBC

Hannah Clarke

The pCR rate was 33% with APL-1202 plus tislelizumab compared with 26% with tislelizumab alone.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.